Incyte (INCY) vs MaxCyte (MXCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Incyte (INCY) has outperformed MaxCyte (MXCT) over the past year, gaining 30.1% versus a loss of 32.9%. Over five years, INCY leads with a +73.0% price change compared with -90.6% for MXCT. Incyte is the larger company by market cap ($23.00 billion vs $101.6 million), about 226.5 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | INCY | MXCT |
|---|---|---|
| Share price | $113.47 | $0.984 |
| Market cap | $23.00B | $101.55M |
| 1-day change | +0.03% | -5.38% |
| YTD return | +14.85% | -32.90% |
| 1-year return | +30.14% | -32.90% |
| 5-year return | +73.03% | -90.57% |
| P/E ratio (TTM) | 14.45 | — |
| Forward P/E | 12.97 | — |
| EPS (TTM) | $7.85 | $-0.34 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $5.14B | — |
| Revenue growth (YoY) | +21.22% | — |
| Net income (latest FY) | $1.29B | — |
| Gross margin | 92.76% | — |
| Operating margin | 29.46% | — |
| Net margin | 25.03% | — |
| 52-week high | $132.60 | $1.87 |
| 52-week low | $82.82 | $0.643 |
| Distance from 52-week high | -14.43% | -47.24% |
| Analyst consensus | buy | — |
| Avg. price target upside | +13.62% | — |
| Average volume | 1.62M | 685.34K |
| Shares outstanding | 202.70M | 103.21M |
| Employees | 2,844 | — |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Commercial Physical & Biological Resarch |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Incyte is about 226.5 times larger than MaxCyte by market value ($23.00B vs $101.55M).
- INCY has outperformed MXCT by 63.0 percentage points over the past year.
About Incyte
INCY stock →Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; MONJUVI/ MINJUVI for the treatment of diffuse large B-cell lymphoma and Follicular Lymphoma; NIKTIMVO for the treatment of chronic graft-versus-host disease.
Health Care · Biotechnology: Commercial Physical & Biological Resarch · 2,844 employees
INCY vs MXCT FAQ
Which is bigger, Incyte or MaxCyte?
Incyte (INCY) is larger, with a market capitalization of $23.00B compared with $101.55M for MaxCyte (MXCT).
Which stock has performed better over the past year, INCY or MXCT?
INCY returned +30.14% over the past 12 months, compared with -32.90% for MXCT (price return, excluding dividends). Past performance does not predict future results.
Are Incyte and MaxCyte in the same industry?
Yes. Both are classified in the Biotechnology: Commercial Physical & Biological Resarch industry within the Health Care sector.